» Articles » PMID: 35935038

Liver X Receptor As a Possible Drug Target for Blood-Brain Barrier Integrity

Overview
Journal Adv Pharm Bull
Date 2022 Aug 8
PMID 35935038
Authors
Affiliations
Soon will be listed here.
Abstract

blood-brain barrier (BBB) is made of specialized cells that are responsible for the selective passage of substances directed to the brain. The integrated BBB is essential for precise controlling of the different substances passage as well as protecting the brain from various damages. In this article, we attempted to explain the role of liver X receptor (LXR) in maintaining BBB integrity as a possible drug target. In this study, various databases, including PubMed, Google Scholar, and Scopus were searched using the following keywords: blood-brain barrier, BBB, liver X receptor, and LXR until July, 2020. Additionally, contents close to the subject of our study were surveyed. LXR is a receptor the roles of which in various diseases have been investigated. LXR can affect maintaining BBB by affecting various ways such as ATP-binding cassette transporter A1 (ABCA1), matrix metalloproteinase-9 (MMP9), insulin-like growth factor 1 (IGF1), nuclear factor-kappa B (NF-κB) signaling, mitogen-activated protein kinase (MAPK), tight junction molecules, both signal transducer and activator of transcription 1 (STAT1), Wnt/β-catenin Signaling, transforming growth factor beta (TGF-β) signaling, and expressions of Smad 2/3 and Snail. LXR could possibly be used either as a target for drug delivery to brain tissue or as a target for maintaining the BBB integrity in different diseases; thereby the drug will be conducted to tissues, other than the brain. If it is verified that only LXRα is necessary for protecting BBB, some specific LXRα ligands must be found and then used in medication.

Citing Articles

Cholesterol metabolism: physiological versus pathological aspects in intracerebral hemorrhage.

Huang R, Pang Q, Zheng L, Lin J, Li H, Wan L Neural Regen Res. 2024; 20(4):1015-1030.

PMID: 38989934 PMC: 11438341. DOI: 10.4103/NRR.NRR-D-23-01462.


LXR agonism for CNS diseases: promises and challenges.

Zhang R, Wuerch E, Yong V, Xue M J Neuroinflammation. 2024; 21(1):97.

PMID: 38627787 PMC: 11022383. DOI: 10.1186/s12974-024-03056-0.


24-Hydroxycholesterol Moderates the Effects of Amyloid-β on Expression of HMG-CoA Reductase and ABCA1 Proteins in Mouse Astrocytes.

Nazeri Z, Mohammadzadeh G, Rashidi M, Azizdoost S, Cheraghzadeh M, Kheirollah A Adv Biomed Res. 2023; 12:167.

PMID: 37564436 PMC: 10410428. DOI: 10.4103/abr.abr_245_22.

References
1.
Soares-Silva M, Diniz F, Gomes G, Bahia D . The Mitogen-Activated Protein Kinase (MAPK) Pathway: Role in Immune Evasion by Trypanosomatids. Front Microbiol. 2016; 7:183. PMC: 4764696. DOI: 10.3389/fmicb.2016.00183. View

2.
Lamouille S, Xu J, Derynck R . Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2014; 15(3):178-96. PMC: 4240281. DOI: 10.1038/nrm3758. View

3.
Russo V, Gluckman P, Feldman E, Werther G . The insulin-like growth factor system and its pleiotropic functions in brain. Endocr Rev. 2005; 26(7):916-43. DOI: 10.1210/er.2004-0024. View

4.
Bonney S, Siegenthaler J . Differential Effects of Retinoic Acid Concentrations in Regulating Blood-Brain Barrier Properties. eNeuro. 2017; 4(3). PMC: 5446490. DOI: 10.1523/ENEURO.0378-16.2017. View

5.
Wu C, Chen C, Lai C, Hung T, Lin C, Chao M . Treatment with TO901317, a synthetic liver X receptor agonist, reduces brain damage and attenuates neuroinflammation in experimental intracerebral hemorrhage. J Neuroinflammation. 2016; 13(1):62. PMC: 4788882. DOI: 10.1186/s12974-016-0524-8. View